We're #hiring a new Head of Talent Management in Dallas, Texas. Apply today or share this post with your network.
Osteal Therapeutics
Pharmaceutical Manufacturing
Dallas, TX 1,835 followers
Revolutionizing the treatment of orthopedic infection. Preserving Limbs. Preserving Lives
About us
Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.
- Website
-
https://www.ostealtx.com/
External link for Osteal Therapeutics
- Industry
- Pharmaceutical Manufacturing
- Company size
- 2-10 employees
- Headquarters
- Dallas, TX
- Type
- Privately Held
Locations
-
Primary
Get directions
Dallas, TX, US
Employees at Osteal Therapeutics
-
Trey Putnam
Experienced biopharmaceutical leader in product development and regulatory affairs.
-
Rob Smodlaka
Senior-level Solutions and Project Management Professional | Matrix Global Pharma | Leadership, Strategy, Execution | Change Agent | Influence…
-
Vic Lam
Senior Director of Supply Chain and Operations
-
Dan Kuehner
Develop, Launch and Manufacture Medical Devices ✦ Scale-Up and Optimize Production Processes and Supply Chains ✦ Build High-Functioning Teams
Updates
-
We are pleased to announce the close of our $50 million oversubscribed Series D equity financing led by new investor, Zimmer Biomet. Thanks to our new and participating existing investors (Johnson & Johnson Innovation – JJDC, Inc., Gideon Strategic Partners, and HM Capital), we remain laser focused on lifting the burden of periprosthetic joint infection for patients, providers and payers. https://bit.ly/4c3UNQc
-
Osteal Therapeutics’ VT-X7 Receives FDA’s Breakthrough Therapy Designation for the treatment of periprosthetic joint infection of the hip and knee and completes enrollment of the pivotal APEX-2 trial. https://bit.ly/3Gqtl1n
Osteal Therapeutics’ VT-X7 Receives FDA’s Breakthrough Therapy Designation for the treatment of periprosthetic joint infection of the hip and knee and completes enrollment of the pivotal APEX-2 trial
globenewswire.com
-
Osteal Therapeutics Closes Over Subscribed Series C Financing. We're able to focus on lifting the burden of periprosthetic joint infection because of the tremendous support from our existing and new investors. Their enthusiasm is validating and energizing. https://bit.ly/45ZVF5A
Osteal Therapeutics Closes $23M Series C Financing
globenewswire.com
-
Our President & CEO, David Thompson, is presenting at #LSIEurope23 in Barcelona this week. If you're attending, make sure you listen to his talk about the amazing journey Osteal Therapeutics is on to lift the burden of periprosthetic joint infection. #LSIAlumni #medtech
-